Autotelic Bio, an RNA based ASO (Anti-sense Oligonucleotide) innovative new drug development company, announced that it has successfully completed a Series B round investment, raising KRW 15.5 billion. 

In this Series B funding, previous investors, including UTC investment, Stonebridge Ventures and Mega Investment participaed, along with new investors such as IBK, Sejong Venture Partners, Dt& Investment, Colopl Next (Co-GP), Woori Bank, Magna Investment, Dreamstone Private Equity (Co-GP), LSK Investment, and Solidus Investment as financial investors.

The secured funding will be focused on conducting clinical research and global business development of immuno-therapeutic anticancer agent and the fixed dose combination new drug of hypertension and type 2 diabetes.